

Devidas Menon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4393720/publications.pdf>

Version: 2024-02-01

64
papers

1,477
citations

331670

21
h-index

345221

36
g-index

68
all docs

68
docs citations

68
times ranked

1774
citing authors

#	ARTICLE	IF	CITATIONS
1	Health Insurance Exemptions for Older Ghanaians: Stakeholder Perspectives on Challenges Confronting an Ambitious Policy. <i>Journal of Aging and Social Policy</i> , 2022, , 1-19.	1.6	0
2	Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review. <i>BMC Health Services Research</i> , 2022, 22, 557.	2.2	14
3	Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review. <i>BMC Health Services Research</i> , 2022, 22, 646.	2.2	3
4	HTA decision-making for drugs for rare diseases: comparison of processes across countries. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, .	2.7	12
5	Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana. <i>Social Science and Medicine</i> , 2021, 270, 113659.	3.8	7
6	“Our Home Is a Muddy Structure” Perceptions of Housing and Health Risks Among Older Adults in Contrasting Neighborhoods in Ghana. <i>Frontiers in Public Health</i> , 2021, 9, 650861.	2.7	2
7	Health, quality of life, and wellbeing of older slum dwellers in sub-Saharan Africa: A scoping review. <i>Global Public Health</i> , 2020, 16, 1-19.	2.0	4
8	Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 87-95.	0.5	21
9	Robot-assisted coronary artery bypass surgery: a systematic review and meta-analysis of comparative studies. <i>Canadian Journal of Surgery</i> , 2020, 63, E491-E508.	1.2	12
10	Tracing the Decisions That Shaped the Development of MyChart, an Electronic Patient Portal in Alberta, Canada: Historical Research Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e17505.	4.3	11
11	Patient Portal Implementation and Uptake: Qualitative Comparative Case Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e18973.	4.3	20
12	Capturing the Impact of Patient Portals Based on the Quadruple Aim and Benefits Evaluation Frameworks: Scoping Review. <i>Journal of Medical Internet Research</i> , 2020, 22, e24568.	4.3	15
13	Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 127.	2.7	4
14	The Introduction of New Non-Drug Health Technologies (NDTs) into Canadian Healthcare Institutions: Opportunities and Challenges. <i>Healthcare Policy</i> , 2019, 15, 95-106.	0.6	2
15	Decision-Making on New Non-Drug Health Technologies (NDTs) by Hospitals and Health Authorities in Canada. <i>Healthcare Policy</i> , 2019, 15, 82-94.	0.6	3
16	Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study. <i>Patient</i> , 2018, 11, 353-359.	2.7	6
17	A checklist for managed access programmes for reimbursement co-designed by Canadian patients and caregivers. <i>Health Expectations</i> , 2018, 21, 973-980.	2.6	6
18	Palliative care in the home: a scoping review of study quality, primary outcomes, and thematic component analysis. <i>BMC Palliative Care</i> , 2018, 17, 41.	1.8	23

#	ARTICLE	IF	CITATIONS
19	The Medical Devices Special Access Program in Canada: A Scoping Study. <i>Healthcare Policy</i> , 2018, 13, 40-57.	0.6	2
20	Explicating social values for resource allocation decisions on new cancer technologies: We, the jury, findâ. <i>Journal of Cancer Policy</i> , 2017, 14, 5-10.	1.4	6
21	Ultra-orphan drugs: can we afford the price. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 611-612.	0.8	1
22	Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 188.	2.7	21
23	Challenges with implementing malaria rapid diagnostic tests at primary care facilities in a Ghanaian district: a qualitative study. <i>Malaria Journal</i> , 2016, 15, 126.	2.3	36
24	DEFINING ELIGIBILITY CRITERIA FOR FUNDING POLICIES AROUND IN VITRO FERTILIZATION. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 426-433.	0.5	1
25	Assisted Reproductive Technologies in Alberta: An Economic Analysis to Inform Policy Decision-Making. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 1122-1130.	0.7	3
26	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. <i>Healthcare Policy</i> , 2015, 10, 24-46.	0.6	3
27	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. <i>Healthcare Policy</i> , 2015, 11, 15-32.	0.6	13
28	Health technology assessment: the journey continues. <i>Cmaj</i> , 2015, 187, E19-E20.	2.0	6
29	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. <i>American Heart Journal</i> , 2015, 169, 122-131.e22.	2.7	24
30	Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?. <i>Patient</i> , 2015, 8, 29-39.	2.7	23
31	Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle. <i>Patient</i> , 2015, 8, 103-117.	2.7	14
32	Introduction of a new health technology into a provincial health system. <i>Healthcare Management Forum</i> , 2015, 28, 210-214.	1.4	0
33	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. <i>Healthcare Policy</i> , 2015, 10, 24-46.	0.6	5
34	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. <i>Healthcare Policy</i> , 2015, 11, 15-32.	0.6	13
35	Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development. <i>Reproductive Health</i> , 2014, 11, 76.	3.1	26
36	Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. <i>Journal of Cancer Policy</i> , 2014, 2, 81-88.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Transparency in Reimbursement Decisions: In Whose Best Interest?. <i>Pharmacoeconomics</i> , 2014, 32, 725-727.	3.3	0
38	An international survey of assisted reproductive technologies (ARTs) policies and the effects of these policies on costs, utilization, and health outcomes. <i>Health Policy</i> , 2014, 116, 238-263.	3.0	13
39	Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. <i>Canadian Urological Association Journal</i> , 2013, 2, 1.	0.6	14
40	Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. <i>PLoS ONE</i> , 2013, 8, e80661.	2.5	86
41	Health Technology Funding Decision-Making Processes Around the World. <i>Pharmacoeconomics</i> , 2011, 29, 475-495.	3.3	64
42	To Fund or Not to Fund. <i>Pharmacoeconomics</i> , 2011, 29, 771-780.	3.3	30
43	Access with Evidence Development: An Approach to Introducing Promising New Technologies into Healthcare. <i>Healthcare Management Forum</i> , 2011, 24, 42-48.	1.4	7
44	Role of patient and public participation in health technology assessment and coverage decisions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 75-89.	1.4	73
45	Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. <i>BMC Gastroenterology</i> , 2010, 10, 111.	2.0	45
46	Access with Evidence Development Schemes. <i>Pharmacoeconomics</i> , 2010, 28, 143-152.	3.3	71
47	Funding the Unfundable. <i>Pharmacoeconomics</i> , 2010, 28, 113-142.	3.3	120
48	Principles of Design of Access with Evidence Development Approaches. <i>Pharmacoeconomics</i> , 2010, 28, 109-111.	3.3	37
49	The role of surgeons in identifying emerging technologies for health technology assessment. <i>Canadian Journal of Surgery</i> , 2010, 53, 86-92.	1.2	11
50	Health Technology Assessment in Canada: 20 Years Strong?. <i>Value in Health</i> , 2009, 12, S14-S19.	0.3	48
51	The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond. <i>Value in Health</i> , 2008, 11, 771-783.	0.3	95
52	Engaging the public in priority-setting for health technology assessment: findings from a citizens' jury. <i>Health Expectations</i> , 2008, 11, 282-293.	2.6	97
53	Priority-setting for healthcare: Who, how, and is it fair?. <i>Health Policy</i> , 2007, 84, 220-233.	3.0	37
54	Cerebral protection devices for use during carotid artery angioplasty with stenting: A health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2006, 22, 119-129.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Bridging the "Know-Do" Gap in Healthcare Priority-Setting: What Role Has Academic Research Played?. Healthcare Management Forum, 2005, 18, 26-32.	1.4	5
56	Access to Drugs for Cancer. Canadian Journal of Public Health, 2005, 96, 454-458.	2.3	43
57	Inter-Provincial Variation in Government Drug Formularies. Canadian Journal of Public Health, 2001, 92, 307-312.	2.3	42
58	Pharmaceutical Cost Control In Canada: Does It Work?. Health Affairs, 2001, 20, 92-103.	5.2	27
59	HEALTH TECHNOLOGY ASSESSMENT IN CANADA A Decade in Review. International Journal of Technology Assessment in Health Care, 2000, 16, 896-902.	0.5	26
60	An Assessment of Health Technology Assessment in Canada. Canadian Journal of Public Health, 2000, 91, 120-120.	2.3	2
61	The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics, 1999, 15, 459-468.	3.3	42
62	The Development of a Health Technology Assessment Program: The Case of Alberta. International Journal of Technology Assessment in Health Care, 1995, 11, 93-101.	0.5	5
63	Evaluation of Cerebral Blood Flow in Arteriovenous Malformations by the Xenon 133 Inhalation Method. Canadian Journal of Neurological Sciences, 1979, 6, 411-416.	0.5	18
64	Regional Cerebral Blood Flow in Patients with Aneurysms: Estimation by Xenon 133 Inhalation. Canadian Journal of Neurological Sciences, 1978, 5, 301-305.	0.5	39